This is my third Ultragenyx (NASDAQ: RARE ) article, following 03/2024's "Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet". Ultragenx has had a rough go since the publication of No Visible Path , with itsWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ...